Article on Formulation and Evaluation of Itraconazole Anti-Fungal Emulsion

Abstract

Fungalinfectionshavebecomeaseriousandgrowinghealthconcernworldwide,particularlyamong immune compromised individuals such as HIV/AIDS patients, diabetics, and those undergoing cancer chemotherapy. Itraconazole,abroad-spectrumtriazoleantifungalagent,iswidelyusedforthe treatment of superficial and systemic fungal infections caused by Candida species, Aspergillus species, and various dermatophytes. However, its clinical utility is significantly limited by its extremelypooraqueoussolubilityandinconsistentoralbioavailability,asitbelongstoBCSClassII categoryofdrugs. This study focuses on the formulation and evaluation of an oil-in-water (o/w) emulsion of itraconazole fororaladministration,usingIndianPharmacopoeia(IP)gradeexcipients.TheformulationwasdevelopedusingCastorOilIPastheoilphase,AcaciaIPandPolysorbate80astheemulsifyingagents,andGlycerinIPasaviscosityenhancingstabilizertopreventphaseseparation.Threeformulations(F1,F2,F3)werepreparedbyvaryingtheconcentrationsofAcaciaandGlycerinandevaluatedforvariousphysicochemicalparameter. Thepreparedemulsionswereevaluatedfororganolepticproperties,pH,viscosity,homogeneity,odprotipmleiztesdize,creamingindex,drugcontent,andstabilitystudies.Theresultsshowedthattheformulationproducedastable,uniform,andpatient-acceptableemulsionwithimproveddrug solubilization and promising drug release profile. The liquid dosage form makes it particularly suitable forpediatric,geriatric,anddysphagicpatientswhofacedifficultyswallowingconventionalcapsule formulations

Introduction

This study focuses on the formulation and evaluation of an oral oil-in-water (O/W) emulsion of Itraconazole, a broad-spectrum triazole antifungal drug used to treat various fungal infections. Fungal infections (mycoses) range from superficial skin diseases to severe systemic infections and have become increasingly common, particularly among immunocompromised individuals such as patients with HIV/AIDS, diabetes, cancer, or organ transplants.

Itraconazole works by inhibiting 14-α demethylase, an enzyme required for ergosterol synthesis in fungal cell membranes, ultimately leading to fungal cell death. However, it is classified as a BCS Class II drug, meaning it has high permeability but very poor water solubility, resulting in low and variable oral bioavailability when administered as conventional capsules or tablets.

To overcome these limitations, the study proposes an oral oil-in-water emulsion in which itraconazole is pre-dissolved in the oil phase. This approach improves drug dissolution, enhances absorption through lymphatic transport, reduces first-pass metabolism, and increases bioavailability. The liquid dosage form is particularly beneficial for pediatric, elderly, and critically ill patients who may have difficulty swallowing capsules and require accurate dose adjustment.

The paper also reviews major types of fungal infections, including:

• Superficial mycoses
• Cutaneous mycoses (dermatophytosis)
• Subcutaneous mycoses
• Systemic/invasive mycoses
• Opportunistic mycoses
• Oral candidiasis (thrush)
• Onychomycosis (nail fungal infection)

Common symptoms include itching, skin redness, oral white plaques, nail discoloration, fever, cough, swallowing difficulties, and neurological symptoms in severe infections. Major risk factors include weakened immunity, prolonged antibiotic or corticosteroid use, environmental exposure to fungi, poor hygiene, hospitalization, and aging.

The pathophysiology of candidiasis involves the transformation of Candida albicans into an invasive form that damages tissues and may spread systemically. Dermatophytosis occurs when dermatophytes invade keratinized tissues using keratin-degrading enzymes, causing characteristic ring-shaped lesions and nail infections.

The emulsion was prepared using the Dry Gum Method, employing pharmaceutical-grade ingredients such as:

• Itraconazole (drug)
• Castor Oil (oil phase)
• Acacia (primary emulsifier)
• Polysorbate 80 (co-emulsifier)
• Glycerin (humectant and viscosity enhancer)
• Methyl Paraben (preservative)
• Citric Acid (pH adjuster)
• Purified Water

The preparation process involves forming a primary emulsion using acacia and castor oil, incorporating itraconazole, adding stabilizing excipients, adjusting pH to 4.5–5.0, and homogenizing the mixture to obtain a stable emulsion.

The study concludes that a stable oral itraconazole emulsion can potentially improve drug solubility, absorption, patient compliance, dose flexibility, and therapeutic effectiveness while reducing variability associated with conventional oral dosage forms. Such a formulation could offer a practical and patient-friendly alternative for the treatment of a wide range of fungal infections.

Conclusion

Itraconazole-based oil-in-water emulsion represents a highly promising and pharmaceutically innovative approach for the oral delivery of this poorly water-soluble antifungal drug. The formulation wassuccessfullypreparedusingminimal IndianPharmacopoeiagradeexcipients—CastorOilIPas the oil phase, Acacia IP and Polysorbate 80 as the emulsifying system, and Glycerin IP as a viscosity-enhancingstabilizer—ina30mLbatchsize. The dry gum method of emulsion preparation produced a stable, uniform, and creamy white emulsion withnophase separation.Theoptimizedformulationdemonstratedacceptablephysicochemical properties including appropriate pH (4.5–5.0), adequate viscosity, uniform droplet size distribution,satisfactorydrugcontent,andgoodphysicalstabilityonacceleratedtesting. Theemulsiondosageformeffectivelyovercomesthemajorlimitationsofconventionalitraconazolecapsulesnamelypooranderraticoralbioavailability—bypre-dissolvingthedrugintheoilphase and enhancing absorption through the lymphatic pathway. This approach minimizes first-pass hepatic metabolismandproducesmorereliableandconsistenttherapeuticdruglevelsinthebloodstream. Furthermore,theliquidnatureoftheformulationmakesitparticularlysuitableandpatientfriendlyforpediatricpatients,elderlyindividuals,andthosewithswallowingdifficulties,whorepresenta significant proportion of patients requiring antifungal therapy. The formulation offers the additionaladvantageofallowingprecise,weight-baseddosinginchildren. Inconclusion,theitraconazoleantifungalemulsionformulatedusingIPgradeexcipientsstandsasasafe,effective,stable,andpatient-friendly oraldosageformthatofferssignificanttherapeuticadvantagesoverconventionalsolidformulations,andholdsgreatpotentialforfurtherdevelopmentandclinicalapplicationinthetreatmentoffungalinfections.

References

[1] TheTheoryandPracticeofIndustrialPharmacyLachmanL.,LiebermanH.A.,KanigJ.L.,2009,3rdEdition,CBSPublishers&Distributors,NewDelhi,pg.no.293–310. [2] Indian Pharmacopoeia — Government of India, Ministry of Health & Family Welfare, 2022, Vol.I,II&III,IndianPharmacopoeiaCommission,Ghaziabad,pg.no.102–110. [3] Essentials of Medical Pharmacology — Tripathi K.D., 2021, 8th Edition, Jaypee Brothers MedicalPublishers,NewDelhi,pg.no.767–780. [4] Biopharmaceutics and Pharmacokinetics — Brahmankar D.M., Edition,VallabhPrakashan,NewDelhi,pg.no.210–225. JaiswalS.B.,2015,2nd [5] Pharmaceutical Analysis Vol. I & II — Kasture A.V., Mahadik K.R., Wadodkar S.G., More H.N.,2016,17thEdition,NiraliPrakashan,Pune,pg.no.3.1–3.12. [6] Textbook of Pharmaceutics — Carter S.J., 2018, CBS Publishers & Distributors, New Delhi, pg. no. 180–210. [7] Practical Physical Pharmacy — Yadav A.V., Pawar A.Y., 2015, 1st Edition, Nirali Prakashan, Pune,pg.no.45–52. [8] Textbook of Pharmacognosy — Kokate C.K., Purohit A.P., Gokhale S.B., 2020, 50th Edition, NiraliPrakashan,Pune,pg.no.7.1–7.10. [9] harmaceutical Microbiology — Jain N.K., 2018, Vallabh Prakashan, New Delhi, pg. no. 130–140. [10] PharmaceuticalJurisprudence — Mithal B.M., 2019, Vallabh Prakashan, New Delhi, pg. no. 88–95. [11] QualityAssurance Techniques in Pharmaceutical Industry — Ansari S.H., 2014, 1st Edition, CBSPublishers&Distributors,NewDelhi,pg.no.88–95. [12] Pharmaceutical Engineering — Subrahmanyam C.V.S., 2017, 2nd Edition, Vallabh Prakashan, NewDelhi,pg.no.78–85. [13] Handbook ofExcipients—RoweR.C.,SheskeyP.J.,QuinnM.E.,2009,6thEdition, PharmaceuticalPress,London,pg.no.155–162,440–445. [14] Pharmaceutical Technology — Aulton M.E., 2013, 4th Edition, Churchill Livingstone Elsevier,Edinburgh,pg.no.435–460. [15] Remington—TheScienceandPracticeofPharmacy—AllenL.V.,2012,22ndEdition, PharmaceuticalPress,London,pg.no.670–680

Copyright

Copyright © 2026 Akanksha Premdas Chavan, Ass. Prof. Vidya Raosaheb Kale. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.